Dinah S. Singer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dinah S. Singer has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Ballachanda N. Devaiah
13 shared publicationsJocelyn D. Weissman
Experimental Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
12 shared publicationsAnne Gegonne
Experimental Immunology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
10 shared publicationsJie Mu
Experimental Immunology Branch, NCI, NIH, Bethesda, MD 20892, USA
7 shared publicationsDaoud Meerzaman
Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD 20892, USA
5 shared publicationsAparna Kotekar
NIH Center for Human Immunology, Inflammation, and Autoimmunity (CHI), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, USA
4 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Elsevier in Journal of Biological Chemistry
HDAC inhibition drives NOX5-dependent oxidative stress and sensitizes uveal melanoma cells to SOD1 inhibition
- 2 November 2026
- Published by Elsevier in Journal of Biological Chemistry
Open AccessHDAC inhibition drives NOX5-dependent oxidative stress and sensitizes uveal melanoma cells to SOD1 inhibition
- Open Access
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1855716
TAF7 accumulates in the cytoplasm during cellular transformation and engages STAT3, WASH, and CCT
TAF7, a core subunit of the general transcription factor TFIID, regulates transcription and additionally functions as an RNA chaperone that directs nascent nuclear RNAs to cytoplasmic polysomes, thereby influencing protein synthesis. Here, we identify a set of novel cytoplasmic interactors and a previously unappreciated cytoplasmic role for TAF7 in oncogenesis. BioID-mediated proximity labeling identified STAT3 and the CCT and WASH complexes as prominent cytoplasmic interactors of TAF7. These interactions were validated by co-immunoprecipitation and proximity ligation assays. We further showed that cytoplasmic TAF7 levels increased during oncogenesis in proportion to cancer cell pathogenicity. Notably, TAF7 engagement with STAT3, CCT and WASH complexes is markedly enhanced during cellular transformation, consistent with their functions in cancer progression. Together, these findings reveal a cytoplasmic TAF7 interactome and implicate elevated cytoplasmic TAF7 as associated with oncogenesis.
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1855716
Open AccessTAF7 accumulates in the cytoplasm during cellular transformation and engages STAT3, WASH, and CCT
TAF7, a core subunit of the general transcription factor TFIID, regulates transcription and additionally functions as an RNA chaperone that directs nascent nuclear RNAs to cytoplasmic polysomes, thereby influencing protein synthesis. Here, we identify a set of novel cytoplasmic interactors and a previously unappreciated cytoplasmic role for TAF7 in oncogenesis. BioID-mediated proximity labeling identified STAT3 and the CCT and WASH complexes as prominent cytoplasmic interactors of TAF7. These interactions were validated by co-immunoprecipitation and proximity ligation assays. We further showed that cytoplasmic TAF7 levels increased during oncogenesis in proportion to cancer cell pathogenicity. Notably, TAF7 engagement with STAT3, CCT and WASH complexes is markedly enhanced during cellular transformation, consistent with their functions in cancer progression. Together, these findings reveal a cytoplasmic TAF7 interactome and implicate elevated cytoplasmic TAF7 as associated with oncogenesis.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 633-636
The Five New Cancer Grand Challenges Teams Taking on the Biggest Questions in Cancer Research
Summary: Cancer Grand Challenges is an international research initiative, galvanizing the global research community to take on cancer’s toughest challenges through interdisciplinary team science. In this article, we introduce our five new teams, each awarded up to $25 million and their creative approaches to tackle five of our latest challenges.
- 4 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (4) , 633-636
Open AccessThe Five New Cancer Grand Challenges Teams Taking on the Biggest Questions in Cancer Research
Summary: Cancer Grand Challenges is an international research initiative, galvanizing the global research community to take on cancer’s toughest challenges through interdisciplinary team science. In this article, we introduce our five new teams, each awarded up to $25 million and their creative approaches to tackle five of our latest challenges.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Data from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation
Small-cell lung cancer (SCLC) is a recalcitrant malignancy that urgently needs new therapies. Four master transcription factors (ASCL1, NEUROD1, POU2F3, and YAP1) have been identified in SCLC, and each defines the transcriptome landscape of one molecular subtype. However, these master transcription factors have not been found directly druggable. We hypothesized that blocking their transcriptional coactivator(s) could provide an alternative approach to target these master transcription factors. Here, we identify that BET proteins physically interact with NEUROD1 and function as transcriptional coactivators. Using CRISPR knockout and ChIP-seq, we demonstrate that NEUROD1 plays a critical role in defining the landscapes of BET proteins in the SCLC genome. Blocking BET proteins by inhibitors led to broad suppression of the NEUROD1-target genes, especially those associated with superenhancers, resulting in the inhibition of SCLC growth in vitro and in vivo. LSAMP, a membrane protein in the IgLON family, was identified as one of the NEUROD1-target genes mediating BET inhibitor sensitivity in SCLC. Altogether, our study reveals that BET proteins are essential in regulating NEUROD1 transactivation and are promising targets in SCLC-N subtype tumors.Implications:Our findings suggest that targeting transcriptional coactivators could be a novel approach to blocking the master transcription factors in SCLC for therapeutic purposes.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation
Small-cell lung cancer (SCLC) is a recalcitrant malignancy that urgently needs new therapies. Four master transcription factors (ASCL1, NEUROD1, POU2F3, and YAP1) have been identified in SCLC, and each defines the transcriptome landscape of one molecular subtype. However, these master transcription factors have not been found directly druggable. We hypothesized that blocking their transcriptional coactivator(s) could provide an alternative approach to target these master transcription factors. Here, we identify that BET proteins physically interact with NEUROD1 and function as transcriptional coactivators. Using CRISPR knockout and ChIP-seq, we demonstrate that NEUROD1 plays a critical role in defining the landscapes of BET proteins in the SCLC genome. Blocking BET proteins by inhibitors led to broad suppression of the NEUROD1-target genes, especially those associated with superenhancers, resulting in the inhibition of SCLC growth in vitro and in vivo. LSAMP, a membrane protein in the IgLON family, was identified as one of the NEUROD1-target genes mediating BET inhibitor sensitivity in SCLC. Altogether, our study reveals that BET proteins are essential in regulating NEUROD1 transactivation and are promising targets in SCLC-N subtype tumors.Implications:Our findings suggest that targeting transcriptional coactivators could be a novel approach to blocking the master transcription factors in SCLC for therapeutic purposes.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary tables 5-17 - Data tables generated during RNA-seq and ChIP-seq analysis, and the information on the siRNA screens. from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation
Table S5. The list of genes significantly altered in H446 cells after NEUROD1 KO. Table S6. The list of NEUROD1 peaks identified in H446 control cells (control gRNA, cl.10) Table S7. The list of NEUROD1 target genes identified by BETA. Table S8. Gene Descriptions Table S9. The list of genomic regions singly occupied by BRD4 in H446 control cells (control gRNA cl. 10). Table S10. The list of genes with significantly altered expression after JQ1 treatment (24 hrs, 1µM) in H446 control cells (control gRNA cl.10). Table S11. The list of genes with significantly altered expression after JQ1 treatment (24 hrs, 1µM) in H446 NEUROD1-KO cells (#297 cl.2-1). Table S12. The list of genes with significantly altered expression after JQ1 treatment (24 hours at 0.5µM) in COR-L279 cells. Table S13. The list of NEUROD1-loaded superenhancers in H446 control cells (control gRNA cl.10). Table S14. The list of BRD4-loaded superenhancers in H446 control cells (control gRNA cl.10). Table S15. The list of BRD4-loaded superenhancers in H446 NEUROD1-KO cells (#297 cl.2-1). Table S16. Information on the Qiagen custom siRNA library. Table S17. The list of genes with significantly altered expression in SCLC PDX LX22 following 5-day NHWD-870 treatment (3mg/kg via gavage daily; n=6 /group).
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary tables 5-17 - Data tables generated during RNA-seq and ChIP-seq analysis, and the information on the siRNA screens. from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation
Table S5. The list of genes significantly altered in H446 cells after NEUROD1 KO. Table S6. The list of NEUROD1 peaks identified in H446 control cells (control gRNA, cl.10) Table S7. The list of NEUROD1 target genes identified by BETA. Table S8. Gene Descriptions Table S9. The list of genomic regions singly occupied by BRD4 in H446 control cells (control gRNA cl. 10). Table S10. The list of genes with significantly altered expression after JQ1 treatment (24 hrs, 1µM) in H446 control cells (control gRNA cl.10). Table S11. The list of genes with significantly altered expression after JQ1 treatment (24 hrs, 1µM) in H446 NEUROD1-KO cells (#297 cl.2-1). Table S12. The list of genes with significantly altered expression after JQ1 treatment (24 hours at 0.5µM) in COR-L279 cells. Table S13. The list of NEUROD1-loaded superenhancers in H446 control cells (control gRNA cl.10). Table S14. The list of BRD4-loaded superenhancers in H446 control cells (control gRNA cl.10). Table S15. The list of BRD4-loaded superenhancers in H446 NEUROD1-KO cells (#297 cl.2-1). Table S16. Information on the Qiagen custom siRNA library. Table S17. The list of genes with significantly altered expression in SCLC PDX LX22 following 5-day NHWD-870 treatment (3mg/kg via gavage daily; n=6 /group).
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental methods, supplemental tables 1-4, and supplemental figures 1-14 from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation
Table S1. The list of the SCLC cell lines (N=52) used in this study. Table S2. The list of 384 genes that constitute the NEUROD1 gene signature. Table S3. The siRNA screen results in H446 and COR-L279 cells. Table S4. Sensitivity (IC50) of SCLC lines (N=52) to JQ1 and NHWD-870. Figure S1. Knockout of NEUROD1 by CRISPR in H446 cells. Figure S2. Validation of the H446 NEUROD1 ChIP-seq. Figure S3. BET bromodomain proteins interact with NEUROD1 in H524 cells. Figure S4. BRD4 interacts with ASCL1 in H1963 cells. Figure S5. NEUROD1 KO affects the BRD4 occupancy only in the genomic regions co-occupied by NEUROD1. Figure S6. Neuronal-related pathways are enriched among the NEUROD1-target genes in H446 cells. Figure S7. Validation of the NEUROD1 gene signature using the SCLC RNA-seq dataset in the CCLE. Figure S8. Effects of BETi on NEUROD1 gene expression in H446 cells. Figure S9. The NEUROD1- and BRD4-loaded SEs identified in H446 control and NEUROD1-KO cells and their correlation. Figure S10. The SCLC-N lines are more susceptible to BETi. Figure S11. NEUROD1 KO renders DMS-273 cells resistant to BETi. Figure S12. Effects of NEUROD1 KO on MYC expression and transactivation. Figure S13. LSAMP expression is regulated by both NEUROD1 and BET bromodomain proteins. Figure S14. Correlation between the IC50 values of NHWD-870 and JQ1 in SCLC cell lines (N=28)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental methods, supplemental tables 1-4, and supplemental figures 1-14 from BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation
Table S1. The list of the SCLC cell lines (N=52) used in this study. Table S2. The list of 384 genes that constitute the NEUROD1 gene signature. Table S3. The siRNA screen results in H446 and COR-L279 cells. Table S4. Sensitivity (IC50) of SCLC lines (N=52) to JQ1 and NHWD-870. Figure S1. Knockout of NEUROD1 by CRISPR in H446 cells. Figure S2. Validation of the H446 NEUROD1 ChIP-seq. Figure S3. BET bromodomain proteins interact with NEUROD1 in H524 cells. Figure S4. BRD4 interacts with ASCL1 in H1963 cells. Figure S5. NEUROD1 KO affects the BRD4 occupancy only in the genomic regions co-occupied by NEUROD1. Figure S6. Neuronal-related pathways are enriched among the NEUROD1-target genes in H446 cells. Figure S7. Validation of the NEUROD1 gene signature using the SCLC RNA-seq dataset in the CCLE. Figure S8. Effects of BETi on NEUROD1 gene expression in H446 cells. Figure S9. The NEUROD1- and BRD4-loaded SEs identified in H446 control and NEUROD1-KO cells and their correlation. Figure S10. The SCLC-N lines are more susceptible to BETi. Figure S11. NEUROD1 KO renders DMS-273 cells resistant to BETi. Figure S12. Effects of NEUROD1 KO on MYC expression and transactivation. Figure S13. LSAMP expression is regulated by both NEUROD1 and BET bromodomain proteins. Figure S14. Correlation between the IC50 values of NHWD-870 and JQ1 in SCLC cell lines (N=28)
- Open Access
BRD4 regulates Aurora B kinase activity
BRD4, a pleiotropic regulator of chromatin structure and transcription, plays critical roles in cancer and immune responses. Unlike other transcriptional regulators, BRD4 largely remains bound to chromosomes during early mitosis. Here we report that BRD4 also regulates mitosis through its direct interaction with and phosphorylation of Aurora B kinase, an essential regulator of mitosis. BRD4 binding to Aurora B inhibits its kinase activity, preventing autophosphorylation and phosphorylation of the key mitotic targets histone H3 and MCAK, the mitotic centromere associated kinesin. This inhibition is relieved during metaphase when JNK is activated and phosphorylates BRD4, triggering its transient release from chromatin. Importantly, Aurora B activity during mitosis inversely correlates with BRD4 binding and directly correlates with JNK activation and BRD4 release. Our findings thus reveal a regulatory mechanism whereby Aurora B activity is directly controlled by BRD4, which in turn is regulated by JNK. Significance Statement: BRD4 has been extensively characterized for its role in regulating chromatin structure and transcription. But its function during mitosis has remained unclear. This study reveals a novel mechanism by which BRD4 directly regulates mitotic progression through its interaction with and inhibition of Aurora B kinase, a central player in chromosome segregation. The timely release of BRD4 from chromatin via JNK-mediated phosphorylation enables Aurora B activation at a critical stage of mitosis. These findings uncover a previously unrecognized BRD4–Aurora B–JNK signaling axis that integrates chromatin dynamics with mitotic control, offering new insights into cell cycle regulation and potential therapeutic targets in cancer.
Open AccessBRD4 regulates Aurora B kinase activity
BRD4, a pleiotropic regulator of chromatin structure and transcription, plays critical roles in cancer and immune responses. Unlike other transcriptional regulators, BRD4 largely remains bound to chromosomes during early mitosis. Here we report that BRD4 also regulates mitosis through its direct interaction with and phosphorylation of Aurora B kinase, an essential regulator of mitosis. BRD4 binding to Aurora B inhibits its kinase activity, preventing autophosphorylation and phosphorylation of the key mitotic targets histone H3 and MCAK, the mitotic centromere associated kinesin. This inhibition is relieved during metaphase when JNK is activated and phosphorylates BRD4, triggering its transient release from chromatin. Importantly, Aurora B activity during mitosis inversely correlates with BRD4 binding and directly correlates with JNK activation and BRD4 release. Our findings thus reveal a regulatory mechanism whereby Aurora B activity is directly controlled by BRD4, which in turn is regulated by JNK. Significance Statement: BRD4 has been extensively characterized for its role in regulating chromatin structure and transcription. But its function during mitosis has remained unclear. This study reveals a novel mechanism by which BRD4 directly regulates mitotic progression through its interaction with and inhibition of Aurora B kinase, a central player in chromosome segregation. The timely release of BRD4 from chromatin via JNK-mediated phosphorylation enables Aurora B activation at a critical stage of mitosis. These findings uncover a previously unrecognized BRD4–Aurora B–JNK signaling axis that integrates chromatin dynamics with mitotic control, offering new insights into cell cycle regulation and potential therapeutic targets in cancer.
- Open Access
- 24 October 2024
- Published by Elsevier in Molecular Cell
- Vol. 84 (22) , 4282-4296.e7
Phosphorylation by JNK switches BRD4 functions
- 24 October 2024
- Published by Elsevier in Molecular Cell
- Vol. 84 (22) , 4282-4296.e7
Open AccessPhosphorylation by JNK switches BRD4 functions
- Open Access
- 4 October 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (10) , 1779-1782
Transforming Cancer Research through Informatics
Summary: For more than three decades, concurrent advances in laboratory technologies and computer science have driven the rise of cancer informatics. Today, software tools for cancer research are indispensable to the entire cancer research enterprise.
- 4 October 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (10) , 1779-1782
Open AccessTransforming Cancer Research through Informatics
Summary: For more than three decades, concurrent advances in laboratory technologies and computer science have driven the rise of cancer informatics. Today, software tools for cancer research are indispensable to the entire cancer research enterprise.
- Open Access
- 26 June 2024
- Published by Springer Nature in Chromosoma
- Vol. 133 (3) , 203-216
CCAAT Promoter element regulates transgenerational expression of the MHC class I gene
: Transgenerational gene expression depends on both underlying DNA sequences and epigenetic modifications. The latter, which can result in transmission of variegated gene expression patterns across multiple generations without DNA alterations, has been termed epigenetic inheritance and has been documented in plants, worms, flies and mammals. Whereas transcription factors binding to cognate DNA sequence elements regulate gene expression, the molecular basis for epigenetic inheritance has been linked to histone and DNA modifications and non-coding RNA. Here we report that mutation of the CCAAT box promoter element abrogates NF-Y binding and disrupts the stable transgenerational expression of an MHC class I transgene. Transgenic mice with a mutated CCAAT box in the MHC class I transgene display variegated expression of the transgene among littermates and progeny in multiple independently derived transgenic lines. After 4 generations, CCAAT mutant transgenic lines derived from a single founder stably displayed distinct patterns of expression. Histone modifications and RNA polymerase II binding correlate with expression of CCAAT mutant transgenic lines, whereas DNA methylation and nucleosome occupancy do not. Mutation of the CCAAT box also results in changes to CTCF binding and DNA looping patterns across the transgene that correlate with expression status. These studies identify the CCAAT promoter element as a regulator of stable transgenerational gene expression such that mutation of the CCAAT box results in variegated transgenerational inheritance. Considering that the CCAAT box is present in 30% of eukaryotic promoters, this study provides insights into how fidelity of gene expression patterns is maintained through multiple generations.
- 26 June 2024
- Published by Springer Nature in Chromosoma
- Vol. 133 (3) , 203-216
Open AccessCCAAT Promoter element regulates transgenerational expression of the MHC class I gene
: Transgenerational gene expression depends on both underlying DNA sequences and epigenetic modifications. The latter, which can result in transmission of variegated gene expression patterns across multiple generations without DNA alterations, has been termed epigenetic inheritance and has been documented in plants, worms, flies and mammals. Whereas transcription factors binding to cognate DNA sequence elements regulate gene expression, the molecular basis for epigenetic inheritance has been linked to histone and DNA modifications and non-coding RNA. Here we report that mutation of the CCAAT box promoter element abrogates NF-Y binding and disrupts the stable transgenerational expression of an MHC class I transgene. Transgenic mice with a mutated CCAAT box in the MHC class I transgene display variegated expression of the transgene among littermates and progeny in multiple independently derived transgenic lines. After 4 generations, CCAAT mutant transgenic lines derived from a single founder stably displayed distinct patterns of expression. Histone modifications and RNA polymerase II binding correlate with expression of CCAAT mutant transgenic lines, whereas DNA methylation and nucleosome occupancy do not. Mutation of the CCAAT box also results in changes to CTCF binding and DNA looping patterns across the transgene that correlate with expression status. These studies identify the CCAAT promoter element as a regulator of stable transgenerational gene expression such that mutation of the CCAAT box results in variegated transgenerational inheritance. Considering that the CCAAT box is present in 30% of eukaryotic promoters, this study provides insights into how fidelity of gene expression patterns is maintained through multiple generations.